02 · Clinical Findings
India brings Wegovy into the fatty-liver conversation
1 min readAn approval for MASH turns Wegovy into a broader metabolic-disease story, with access and evidence questions still visible.
India cleared Wegovy’s 2.4 mg semaglutide injection for MASH, placing an obesity medicine inside a fatty-liver treatment conversation in that market.
MASH is a form of fatty-liver disease that can involve inflammation and liver damage, but this regulatory decision does not settle how the medicine will be used or covered elsewhere.
The next useful evidence is how this indication is adopted in practice and whether regulators in other markets take parallel action.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsA review raises a careful question about GLP-1 medicines and binge eatingUCL News · Jul 16, 2026 · scroll to read